GSK Stock Recent News
GSK LATEST HEADLINES
A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price in recent years.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK has been granted US Fast Track designation for bepirovirsen, an investigational treatment for chronic hepatitis B (CHB). A request was made to US regulator the FDA by the UK pharma due to an unmet medical for what is a serious and life-threatening condition, said the statement.
GSK (GSK) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.64 per share a year ago.
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.
British pharmaceutical giant GSK PLC on Tuesday announced a $1.4 billion deal to acquire Aiolos Bio Inc., boosting its respiratory portfolio.
British drugmaker GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment, had met its primary goal of progression free survival in a late-stage trial.
While most computer-chip makers over the past decades have touted the benefits of an ever-shrinking product, a well-funded Silicon Valley company has built what it says is the largest and fastest-ever computer chip, dedicated to AI.
GSK , on Monday, announced an exclusive partnership with China's Chongqing Zhifei Biological Products (Zhifei) for its shingles vaccine.
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japanese authorities have accepted for review a supplementary new drug application (sNDA) for Nucala, a treatment for chronic rhinosinusitis with nasal polyps in adult patients. If approved, Nucala would be the first anti-interleukin-5 biologic available in Japan for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal polyps, the firm said.